Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

Healthcare worker placing Eluvia Drug-Eluting Stent

Eluvia vs. Bare Metal Stents

EMINENT randomized controlled trial results

EMINENT randomized controlled trial results

EMINENT1 is the largest Randomized Controlled Trial (2:1) comparing Eluvia™ Drug-Eluting Vascular Stent System to self-expanding bare metal stents (BMS) for SFA/PPA; EU multi-center; superiority trial; core lab adjudicated.

Download the EMINENT datasheet
See 1-year manuscript

EMINENT RCT 1-year primary patency results

Eluvia demonstrated superiority over BMS2 with a statistically significant primary patency of 85.4% versus 76.3% through 1-Year.

1-Year Kaplan-Meier primary patency estimate

1-Year Primary Kaplen Meijer Patency estimate

Kaplan-Meier Estimate: Primary patency defined as core-lab assessed duplex ultrasound peak systolic velocity ratio (PSVR) ≤ 2.4 at 1-year in the absence of clinically-driven TLR or bypass of the target lesion.

Log-rank p-value compares the entire K-M curves from time point zero to day 395 (full 1-year follow-up window).

EMINENT RCT 1-year primary sustained clinical improvement

Eluvia demonstrated a statistically significant greater rate of sustained clinical improvement without reintervention over BMS through 1-Year.3

EMINENT Trial Eluvia 1 Year Primary Sustained

EMINENT randomized controlled trial details

 Eluvia DES
(n=492)		BMS 
(n=273)		p-value
All Death, Major Amputation, TLR11.8% (56/474)11.8% (31/263)0.9912
All-Cause Death at 1-Year2.7% (13/474)1.1% (3/263)0.1528
Target Limb Major Amputation0.2% (1/474)0.0% (0/263)1.0000
Clinically-Driven Target Lesion Revascularization8.4% (40/474)10.6% (28/263)0.3212
 Eluvia DES
(n=508)		Control 
(n=267)		p-value
Age (Years)68.9 ± 8.7 68.9 ± 9.10.9739
Male Gender71.5%67.4%0.2431
Diabetes Mellitus (medically-treated)31.9%32.6%0.8440
History of Smoking (current/previous)36.0% / 39.6%36.0% / 41.6%0.9849 / 0.5884
Percent Stenosis (%)86.6 ± 15.285.5 ± 15.30.3629
Total Occlusions42.3%39.9%0.5372
Total Stented Length (mm)105.8 ± 48.4109.2 ± 49.80.3858
Target Lesion Length (mm)75.6 ± 50.372.2 ± 47.00.3815
Moderately Calcified21.6%26.0%0.1849
Severely Calcified30.3%31.1%0.8122

Ordering and reimbursement

Get downloads for ordering information and reimbursement coding guides for our drug-eluting technologies.

View all product guides

Stay up to date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Sign up today
Eluvia indications, safety, and warnings
Ranger indications, safety, and warnings

1. EMINENT RCT 1-Year results presented by Yann Gouëffic, MD. VIVA 2021

2. EMINENT Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against commercially-available Self-Expanding Bare Nitinol Stents, single-blind, superiority design; independent core lab adjudication. Primary Endpoint: 1-Year Binary Primary Patency rate of 83.2% in the Eluvia arm vs. 74.3% in the Bare-Metal Stenting arm (p-value = 0.0077).

3. In EMINENT, primary sustained clinical improvement was defined as an improvement (decrease) by at least 1 Rutherford category, without TLR.